ZNTL – zentalis pharmaceuticals, inc. - common stock (US:NASDAQ)
Stock Stats
News
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors [Yahoo! Finance]
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at Guggenheim from $12.00 to $8.00. They now have a "buy" rating on the stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
Form SC 13G/A Zentalis Pharmaceuticals Filed by: CITADEL ADVISORS LLC
Form 4 Zentalis Pharmaceuticals For: Nov 13 Filed by: Myers Scott Dunseth
Form 3 Zentalis Pharmaceuticals For: Nov 13 Filed by: Bruns Ingmar
Form 3 Zentalis Pharmaceuticals For: Nov 13 Filed by: EASTLAND JULIA MARIE
Form 3 Zentalis Pharmaceuticals For: Nov 13 Filed by: Myers Scott Dunseth
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.